Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
14 "Seok Ho Kang"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Genitourinary cancer
Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus without Confirmatory Bone Scan
Chang Wook Jeong, Jang Hee Han, Dong Deuk Kwon, Jae Young Joung, Choung-Soo Kim, Hanjong Ahn, Jun Hyuk Hong, Tae-Hwan Kim, Byung Ha Chung, Seong Soo Jeon, Minyong Kang, Sung Kyu Hong, Tae Young Jung, Sung Woo Park, Seok Joong Yun, Ji Yeol Lee, Seung Hwan Lee, Seok Ho Kang, Cheol Kwak
Cancer Res Treat. 2024;56(2):634-641.   Published online December 5, 2023
DOI: https://doi.org/10.4143/crt.2023.848
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
In men with metastatic castration-resistant prostate cancer (mCRPC), new bone lesions are sometimes not properly categorized through a confirmatory bone scan, and clinical significance of the test itself remains unclear. This study aimed to demonstrate the performance rate of confirmatory bone scans in a real-world setting and their prognostic impact in enzalutamide-treated mCRPC.
Materials and Methods
Patients who received oral enzalutamide for mCRPC during 2014-2017 at 14 tertiary centers in Korea were included. Patients lacking imaging assessment data or insufficient drug exposure were excluded. The primary outcome was overall survival (OS). Secondary outcomes included performance rate of confirmatory bone scans in a real-world setting. Kaplan-Meier analysis and multivariate Cox regression analysis were performed.
Results
Overall, 520 patients with mCRPC were enrolled (240 [26.2%] chemotherapy-naïve and 280 [53.2%] after chemotherapy). Among 352 responders, 92 patients (26.1%) showed new bone lesions in their early bone scan. Confirmatory bone scan was performed in 41 patients (44.6%), and it was associated with prolonged OS in the entire population (median, 30.9 vs. 19.7 months; p < 0.001), as well as in the chemotherapy-naïve (median, 47.2 vs. 20.5 months; p=0.011) and post-chemotherapy sub-groups (median, 25.5 vs. 18.0 months; p=0.006). Multivariate Cox regression showed that confirmatory bone scan performance was an independent prognostic factor for OS (hazard ratio 0.35, 95% confidence interval, 0.18 to 0.69; p=0.002).
Conclusion
Confirmatory bone scan performance was associated with prolonged OS. Thus, the premature discontinuation of enzalutamide without confirmatory bone scans should be discouraged.

Citations

Citations to this article as recorded by  
  • ECM-mimicking hydrogel models of human adipose tissue identify deregulated lipid metabolism in the prostate cancer-adipocyte crosstalk under antiandrogen therapy
    Agathe Bessot, Joan Röhl, Maria Emmerich, Anton Klotz, Akhilandeshwari Ravichandran, Christoph Meinert, David Waugh, Jacqui McGovern, Jenni Gunter, Nathalie Bock
    Materials Today Bio.2025; 30: 101424.     CrossRef
  • 3,425 View
  • 134 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
TNM-Based Head-to-Head Comparison of Urachal Carcinoma and Urothelial Bladder Cancer: Stage-Matched Analysis of a Large Multicenter National Cohort
Sang Hun Song, Jaewon Lee, Young Hwii Ko, Jong Wook Kim, Seung Il Jung, Seok Ho Kang, Jinsung Park, Ho Kyung Seo, Hyung Joon Kim, Byong Chang Jeong, Tae-Hwan Kim, Se Young Choi, Jong Kil Nam, Ja Yoon Ku, Kwan Joong Joo, Won Sik Jang, Young Eun Yoon, Seok Joong Yun, Sung-Hoo Hong, Jong Jin Oh
Cancer Res Treat. 2023;55(4):1337-1345.   Published online April 17, 2023
DOI: https://doi.org/10.4143/crt.2023.417
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Outcome analysis of urachal cancer (UraC) is limited due to the scarcity of cases and different staging methods compared to urothelial bladder cancer (UroBC). We attempted to assess survival outcomes of UraC and compare to UroBC after stage-matched analyses.
Materials and Methods
Total 203 UraC patients from a multicenter database and 373 UroBC patients in single institution from 2000 to 2018 were enrolled (median follow-up, 32 months). Sheldon stage conversion to corresponding TNM staging for UraC was conducted for head-to-head comparison to UroBC. Perioperative clinical variables and pathological results were recorded. Stage-matched analyses for survival by stage were conducted.
Results
UraC patients were younger (mean age, 54 vs. 67 years; p < 0.001), with 163 patients (80.3%) receiving partial cystectomy and 23 patients (11.3%) radical cystectomy. UraC was more likely to harbor ≥ pT3a tumors (78.8% vs. 41.8%). While 5-year recurrence-free survival, cancer-specific survival (CSS) and overall survival were comparable between two groups (63.4%, 67%, and 62.1% in UraC and 61.5%, 75.9%, and 67.8% in UroBC, respectively), generally favorable prognosis for UraC in lower stages (pT1-2) but unfavorable outcomes in higher stages (pT4) compared to UroBC was observed, although only 5-year CSS in ≥ pT4 showed statistical significance (p=0.028). Body mass index (hazard ratio [HR], 0.929), diabetes mellitus (HR, 1.921), pathologic T category (HR, 3.846), and lymphovascular invasion (HR, 1.993) were predictors of CSS for all patients.
Conclusion
Despite differing histology, UraC has comparable prognosis to UroBC with relatively favorable outcome in low stages but worse prognosis in higher stages. The presented system may be useful for future grading and risk stratification of UraC.

Citations

Citations to this article as recorded by  
  • Clinical Presentation and Targeted Interventions in Urachal Adenocarcinoma: A Single-Institution Case Series and Review of Emerging Therapies
    Akshay Mathavan, Akash Mathavan, Rodrigo Murillo-Alvarez, Kriti Gera, Urszula Krekora, Aaron J. Winer, Mohit Mathavan, Ellery Altshuler, Brian Hemendra Ramnaraign
    Clinical Genitourinary Cancer.2024; 22(1): 67.     CrossRef
  • Robotic‐assisted approaches to urachal carcinoma: A comprehensive systematic review of the safety and efficacy outcomes
    Caio Vinícius Suartz, Lucas Motta Martinez, Pedro Henrique Brito, Carlos Victori Neto, Maurício Dener Cordeiro, Luiz Antonio Assan Botelho, Fábio Pescarmona Gallucci, José Maurício Mota, William Carlos Nahas, Leopoldo Alves Ribeiro‐Filho
    BJUI Compass.2024; 5(3): 327.     CrossRef
  • 3,532 View
  • 208 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Genitourinary Cancer
A Predictive Model Based on Bi-parametric Magnetic Resonance Imaging and Clinical Parameters for Clinically Significant Prostate Cancer in the Korean Population
Tae Il Noh, Chang Wan Hyun, Ha Eun Kang, Hyun Jung Jin, Jong Hyun Tae, Ji Sung Shim, Sung Gu Kang, Deuk Jae Sung, Jun Cheon, Jeong Gu Lee, Seok Ho Kang
Cancer Res Treat. 2021;53(4):1148-1155.   Published online December 31, 2020
DOI: https://doi.org/10.4143/crt.2020.1068
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to develop and validate a predictive model for the assessment of clinically significant prostate cancer (csPCa) in men, prior to prostate biopsies, based on bi-parametric magnetic resonance imaging (bpMRI) and clinical parameters.
Materials and Methods
We retrospectively analyzed 300 men with clinical suspicion of prostate cancer (prostate-specific antigen [PSA] ≥ 4.0 ng/mL and/or abnormal findings in a digital rectal examination), who underwent bpMRI-ultrasound fusion transperineal targeted and systematic biopsies in the same session, at a Korean university hospital. Predictive models, based on Prostate Imaging Reporting and Data Systems scores of bpMRI and clinical parameters, were developed to detect csPCa (intermediate/high grade [Gleason score ≥ 3+4]) and compared by analyzing the areas under the curves and decision curves.
Results
A predictive model defined by the combination of bpMRI and clinical parameters (age, PSA density) showed high discriminatory power (area under the curve, 0.861) and resulted in a significant net benefit on decision curve analysis. Applying a probability threshold of 7.5%, 21.6% of men could avoid unnecessary prostate biopsy, while only 1.0% of significant prostate cancers were missed.
Conclusion
This predictive model provided a reliable and measurable means of risk stratification of csPCa, with high discriminatory power and great net benefit. It could be a useful tool for clinical decision-making prior to prostate biopsies.

Citations

Citations to this article as recorded by  
  • Abbreviated MRI Protocols in the Abdomen and Pelvis
    Kristina I. Ringe, Jin Wang, Ying Deng, Shan Pi, Amine Geahchan, Bachir Taouli, Mustafa R. Bashir
    Journal of Magnetic Resonance Imaging.2024; 59(1): 58.     CrossRef
  • Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer
    Arya Haj-Mirzaian, Kristine S. Burk, Ronilda Lacson, Daniel I. Glazer, Sanjay Saini, Adam S. Kibel, Ramin Khorasani
    JAMA Network Open.2024; 7(3): e244258.     CrossRef
  • The Barcelona Predictive Model of Clinically Significant Prostate Cancer
    Juan Morote, Angel Borque-Fernando, Marina Triquell, Anna Celma, Lucas Regis, Manel Escobar, Richard Mast, Inés M. de Torres, María E. Semidey, José M. Abascal, Carles Sola, Pol Servian, Daniel Salvador, Anna Santamaría, Jacques Planas, Luis M. Esteban, E
    Cancers.2022; 14(6): 1589.     CrossRef
  • Efficacy of Tadalafil in Penile Rehabilitation Started Before Nerve-Sparing Robot-Assisted Radical Prostatectomy: A Double-Blind Pilot Study
    Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Seok Ho Kang
    Sexual Medicine.2022; 10(3): 1.     CrossRef
  • Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy
    Juan Morote, Angel Borque-Fernando, Marina Triquell, Anna Celma, Lucas Regis, Richard Mast, Inés M. de Torres, María E. Semidey, José M. Abascal, Pol Servian, Anna Santamaría, Jacques Planas, Luis M. Esteban, Enrique Trilla
    Cancers.2022; 14(10): 2374.     CrossRef
  • Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review
    Marina Triquell, Miriam Campistol, Ana Celma, Lucas Regis, Mercè Cuadras, Jacques Planas, Enrique Trilla, Juan Morote
    Cancers.2022; 14(19): 4747.     CrossRef
  • 6,684 View
  • 165 Download
  • 5 Web of Science
  • 6 Crossref
Close layer
Diagnostic Accuracy and Value of Magnetic Resonance Imaging–Ultrasound Fusion Transperineal Targeted and Template Systematic Prostate Biopsy Based on Bi-parametric Magnetic Resonance Imaging
Tae Il Noh, Jong Hyun Tae, Hyung Keun Kim, Ji Sung Shim, Sung Gu Kang, Deuk Jae Sung, Jun Cheon, Jeong Gu Lee, Seok Ho Kang
Cancer Res Treat. 2020;52(3):714-721.   Published online February 10, 2020
DOI: https://doi.org/10.4143/crt.2019.716
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the diagnostic value of magnetic resonance imaging (MRI)–ultrasound (US) fusion transperineal targeted biopsy (FTB) and fusion template systematic biopsy (FSB) for prostate cancer (PCa) and clinically significant prostate cancer (csPCa) (intermediate/high grade [Gleason score ≥ 3+4]) based on bi-parametric MRI (bpMRI).
Materials and methods
Retrospectively, we analyzed 300 patients with elevated prostate-specific antigen (≥ 4.0 ng/mL) and/or abnormal findings in a digital rectal examination at the Korea University Hospital. All 300 men underwent bpMRI-US fusion transperineal FTB and FSB in the period from April 2017 to March 2019.
Results
PCas were detected in 158 of 300 men (52.7%), and the prevalence of csPCa was 34.0%. CsPCas were detected in 12 of 102 (11.8%) with Prostate Imaging-Reporting and Data System (PI-RADS) 3, 42 of 92 (45.7%) with PI-RADS 4, respectively; and 45 of 62 (72.6%) men with PI-RADS 5, respectively. BpMRI showed a sensitivity of 95.1% and negative predictive value of 89.6% for csPCa. FTB detected additional csPCa in 33 men (12.9%) compared to FSB. Compared to FTB, FSB detected additional csPCa in 10 men (3.9%).
Conclusion
BpMRI-US FTB and FSB improved detection of PCa and csPCa. The accuracy of bi-parametric MRI is comparable with that of multi-parametric MRI. Further, it is rapid, simpler, cheaper, and no side effects of contrast media. Therefore, it is expected that bpMRI-US transperineal FTB and FSB could be a good alternative to conventional US-guided transrectal biopsy, which is the current gold standard.

Citations

Citations to this article as recorded by  
  • Diagnostic performance of transperineal prostate targeted biopsy alone according to the PI-RADS score based on bi-parametric magnetic resonance imaging
    Tae Il Noh, Ji Sung Shim, Seok Ho Kang, Jun Cheon, Sung Gu Kang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Efficacy of Tadalafil in Penile Rehabilitation Started Before Nerve-Sparing Robot-Assisted Radical Prostatectomy: A Double-Blind Pilot Study
    Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Seok Ho Kang
    Sexual Medicine.2022; 10(3): 1.     CrossRef
  • Concordance between biparametric MRI, transperineal targeted plus systematic MRI-ultrasound fusion prostate biopsy, and radical prostatectomy pathology
    Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jeong Gu Lee, Jeong Hyeon Lee, Seok Ho Kang
    Scientific Reports.2022;[Epub]     CrossRef
  • Three-dimensional ultrasound integrating nomogram and the blood flow image for prostate cancer diagnosis and biopsy: A retrospective study
    Dong Chen, Yingjie Niu, Haitao Chen, Dequan Liu, Rong Guo, Nan Yao, Zhiyao Li, Xiaomao Luo, Hongyang Li, Shicong Tang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Comparison between biparametric and multiparametric MRI in predicting muscle invasion by bladder cancer based on the VI-RADS
    Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Deuk Jae Sung, Jun Cheon, Ki Choon Sim, Seok Ho Kang
    Scientific Reports.2022;[Epub]     CrossRef
  • A Predictive Model Based on Bi-parametric Magnetic Resonance Imaging and Clinical Parameters for Clinically Significant Prostate Cancer in the Korean Population
    Tae Il Noh, Chang Wan Hyun, Ha Eun Kang, Hyun Jung Jin, Jong Hyun Tae, Ji Sung Shim, Sung Gu Kang, Deuk Jae Sung, Jun Cheon, Jeong Gu Lee, Seok Ho Kang
    Cancer Research and Treatment.2021; 53(4): 1148.     CrossRef
  • PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer
    Vlad Cristian Munteanu, Raluca Andrada Munteanu, Diana Gulei, Vlad Horia Schitcu, Bogdan Petrut, Ioana Berindan Neagoe, Patriciu Achimas Cadariu, Ioan Coman
    Diagnostics.2020; 10(10): 806.     CrossRef
  • 7,239 View
  • 169 Download
  • 11 Web of Science
  • 7 Crossref
Close layer
Oncologic, Perioperative Outcomes of Female Radical Cystectomy: Results from a Multicenter Study in Korea
Ji Sung Shim, Ho Kyung Seo, Ja Hyeon Ku, Byong Chang Jeong, Bumsik Hong, Seok Ho Kang, UCART (Urothelial Cancer-Advanced Research and Treatment Group in Korea) Group
Cancer Res Treat. 2019;51(3):1064-1072.   Published online October 30, 2018
DOI: https://doi.org/10.4143/crt.2018.515
AbstractAbstract PDFPubReaderePub
Purpose
The lower incidence of bladder cancer among women has led to a lack of information on female radical cystectomy (RC). This study aimed to analyze the characteristics related with female RC in a cohort from multiple academic institutions.
Materials and Methods
This was a retrospective review of 384 female patients who underwent RC for bladder cancer. Epidemiologic, perioperative variables including urologic referral periodwith consequent pathologic stage distributions were assessed. The changes in surgical techniques over time were illustrated. Also, we evaluated recurrence-free survival (RFS) at 2 and 5 years and overall survival (OS) at 5 years with stage-specific analyses using the Kaplan-Meier method.
Results
The mean follow-up time was 35 months (interquartile rage [IQR], 9 to 55). The average time to urologic referral with initial symptoms was 5.5 (IQR, 1 to 6) months and over 20% of patients visited clinics after 6 months. In subsequent stage distributions according to referral period, T2 or higher stage distributions were abruptly increased after 1 year. Overall 2-year/5-year RFS rates were 0.72/0.57 and 5-year OS was 0.61. Notable surgical descriptions were as follows: 91% of patients underwent open RC; 80% of patients underwent an ileal conduit; and 83% of patients received anterior exenteration. However, the proportions of robotic surgery, orthotopic neobladder and organ sparing cystectomy have increased recen-tly.
Conclusion
We identified the general characteristics and changes in pattern of female RC. Our results also suggest that women are susceptible to delays in referral to an urologist and are at greater risk for worse prognosis.

Citations

Citations to this article as recorded by  
  • Perioperative, oncological, and survival outcomes of robotic radical cystectomy with urinary diversion in females
    Varun V. Agarwal, B. Yuvaraja Thyavihally, Santosh Subhash Waigankar, Preetham Dev, Abhinav P. Pednekar, Diptiman Roy, Nevitha Athikari, Meenal Hastak, Naresh Badlani, D. Harshwardhan Pokharkar, Nagaraja Sekhar Ayyalasomayajula, Archan Khandekar, Ashish A
    Indian Journal of Urology.2023; 39(1): 27.     CrossRef
  • Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage
    Sunil H. Patel, Shirley Wang, Meredith R. Metcalf, Natasha Gupta, Andrew Gabrielson, Esther Lee, Mary Rostom, Phil Pierorazio, Armine Smith, Noah Hahn, Mark Schoenberg, Max Kates, Jean Hoffman-Censits, Trinity J. Bivalacqua
    Clinical Genitourinary Cancer.2022; 20(1): 60.     CrossRef
  • The learning curve for robot-assisted radical cystectomy with total intracorporeal urinary diversion based on radical cystectomy pentafecta
    Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jong Hyun Pyun, Seok Ho Kang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 6,961 View
  • 144 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Laparoscopy versus Open Nephroureterectomy in Prognostic Outcome of Patients with Advanced Upper Tract Urothelial Cancer: A Retrospective, Multicenter, Propensity-Score Matching Analysis
Sung Han Kim, Mi Kyung Song, Jung Kwon Kim, Bumsik Hong, Seok Ho Kang, Ja Hyeon Ku, Byong Chang Jeong, Ho Kyung Seo, On behalf of Urothelial Cancer-Advanced Research and Treatment (UCART) Study Group
Cancer Res Treat. 2019;51(3):963-972.   Published online October 12, 2018
DOI: https://doi.org/10.4143/crt.2018.465
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to compare oncologic outcomes between open nephroureterectomy (ONU) and laparoscopic nephroureterectomy (LNU) in patients with upper tract urothelial carcinoma.
Materials and Methods
The medical records of consecutive ONU and LNU cases from five tertiary institutions were retrospectively analyzed between 2000 and 2012. The propensity-score matching methodology was used to compare the two surgical approaches in terms of age, body mass index, American Society of Anesthesiologists score, tumor location, grade, pathologic T and N categories, the presence of lymphovascular invasion, and follow-up duration. The Kaplan-Meier with log-rank tests and clustered Cox regression were used to compare the estimated rates of survival for each surgical approach and to investigate the effect of the surgical approach on each prognostic outcome.
Results
Six hundred thirty-eight propensity-score matching pairs (n=1,276) were compared; LNU was significantly better than ONU in all types of survival, including intravesical recurrencefree survival (IVRFS), disease-free survival, overall survival (OS), and cancer-specific survival (CSS) (p < 0.05). The 3-year OS and CSS rates were significantly higher with LNU than with ONU (p < 0.05). Compared with ONU, LNU had significantly better 3-year OS and CSS rates (82.9% and 86.2% vs. 78.3% and 81.8%); there were no differences at 5 years. In subgroup analysis of the early-staged group, advanced-stage group, lymph node–positive group, and lymph node–negative group, the two approaches did not significantly affect prognostic outcomes, except LNU improved the IVRFS in the lymph node–negative or no history of previous bladder cancer group.
Conclusion
LNU had a significantly better prognostic outcome than ONU after propensity-score matching.

Citations

Citations to this article as recorded by  
  • Laparoscopic Versus Open Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Propensity-Score Matched Studies
    Shidong Deng, Lingzhi Liu, Yurou Wang, Chuan Zhou, Huihui Zhang
    Surgical Innovation.2024; 31(5): 520.     CrossRef
  • Differential effect of surgical technique on intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial cancer: a systematic review and Meta-analysis
    Ichiro Tsuboi, Akihiro Matsukawa, Mehdi Kardoust Parizi, Jakob Klemm, Robert J Schulz, Anna Cadenar, Stefano Mancon, Sever Chiujdea, Tamás Fazekas, Marcin Miszczyk, Ekaterina Laukhtina, Tatsushi Kawada, Satoshi Katayama, Takehiro Iwata, Kensuke Bekku, Koi
    World Journal of Urology.2024;[Epub]     CrossRef
  • Comparing Oncological and Perioperative Outcomes of Open versus Laparoscopic versus Robotic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Multicenter, Multinational, Propensity Score-Matched Analysis
    Nico C. Grossmann, Francesco Soria, Tristan Juvet, Aaron M. Potretzke, Hooman Djaladat, Alireza Ghoreifi, Eiji Kikuchi, Andrea Mari, Zine-Eddine Khene, Kazutoshi Fujita, Jay D. Raman, Alberto Breda, Matteo Fontana, John P. Sfakianos, John L. Pfail, Ekater
    Cancers.2023; 15(5): 1409.     CrossRef
  • Factors Predicting Oncological Outcomes of Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma in Taiwan
    I-Hsuan Alan Chen, Chao-Hsiang Chang, Chi-Ping Huang, Wen-Jeng Wu, Ching-Chia Li, Chung-Hsin Chen, Chao-Yuan Huang, Chi-Wen Lo, Chih-Chin Yu, Chung-You Tsai, Wei-Che Wu, Jen-Shu Tseng, Wun-Rong Lin, Yuan-Hong Jiang, Yu-Khun Lee, Yeong-Chin Jou, Ian-Seng C
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Robotic Radical Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma: A Trend Analysis of Utilization and a Comparative Study
    Hoyoung Bae, Jae Hoon Chung, Wan Song, Minyong Kang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Hyun Hwan Sung
    Cancers.2022; 14(10): 2497.     CrossRef
  • Oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: an updated meta-analysis
    Radosław Piszczek, Łukasz Nowak, Wojciech Krajewski, Joanna Chorbińska, Sławomir Poletajew, Marco Moschini, Krzysztof Kaliszewski, Romuald Zdrojowy
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • Laparoscopic compared with open nephroureterectomy in upper urinary tract urothelial carcinoma: A systemic review and a meta‐analysis
    Guihong Liu, Zeqin Yao, Guoqiang Chen, Yalang Li, Bing Liang
    International Journal of Clinical Practice.2021;[Epub]     CrossRef
  • RETRACTED: Open Nephroureterectomy Compared to Laparoscopic in Upper Urinary Tract Urothelial Carcinoma: A Meta-Analysis
    Guihong Liu, Zeqin Yao, Guoqiang Chen, Yalang Li, Bing Liang
    Frontiers in Surgery.2021;[Epub]     CrossRef
  • A retrospective multicenter comparison of conditional cancer-specific survival between laparoscopic and open radical nephroureterectomy in locally advanced upper tract urothelial carcinoma
    Sung Han Kim, Mi Kyung Song, Ja Hyeon Ku, Seok Ho Kang, Byong Chang Jeong, Bumsik Hong, Ho Kyung Seo, Isaac Yi Kim
    PLOS ONE.2021; 16(10): e0255965.     CrossRef
  • Risk factor analysis of intravesical recurrence after retroperitoneoscopic nephroureterectomy for upper tract urothelial carcinoma
    Masato Yanagi, Tsutomu Hamasaki, Jun Akatsuka, Yuki Endo, Hayato Takeda, Yukihiro Kondo
    BMC Urology.2021;[Epub]     CrossRef
  • Diagnosis, management, and follow-up of upper tract urothelial carcinoma: an interdisciplinary collaboration between urology and radiology
    Jacob L. Roberts, Fady Ghali, Lejla Aganovic, Seth Bechis, Kelly Healy, Gerant Rivera-Sanfeliz, Riccardo Autorino, Ithaar Derweesh
    Abdominal Radiology.2019; 44(12): 3893.     CrossRef
  • Prognostic Value of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
    Wen Liu, Lijiang Sun, Fengju Guan, Fangming Wang, Guiming Zhang
    Disease Markers.2019; 2019: 1.     CrossRef
  • 7,677 View
  • 180 Download
  • 12 Web of Science
  • 12 Crossref
Close layer
Health-Related Quality of Life, Perceived Social Support, and Depression in Disease-Free Survivors Who Underwent Curative Surgery Only for Prostate, Kidney and Bladder Cancer: Comparison among Survivors and with the General Population
Dong Wook Shin, Hyun Sik Park, Sang Hyub Lee, Seung Hyun Jeon, Seok Cho, Seok Ho Kang, Seung Chol Park, Jong Hyock Park, Jinsung Park
Cancer Res Treat. 2019;51(1):289-299.   Published online May 4, 2018
DOI: https://doi.org/10.4143/crt.2018.053
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to compare health-related quality of life (HRQoL) of disease-free prostate (PC), kidney (KC), and bladder cancer (BC) survivors with that of the general population.
Materials and Methods
Our study included 331 urological cancer (UC) survivors (114 PC, 108 KC, and 109 BC) aged ≥ 50 years disease-free for at least 1 year after surgery. The control group included 1,177 subjects without a history of cancer. The HRQoL was assessed using the European Organization for Research and Treatment of Cancer QLQ-C30, the Duke-UNC Functional Social Support Questionnaire, and the Patient Health Questionnaire-9.
Results
There was no significant difference between the groups in terms of any of the functioning sub-scales and symptoms, except significantly lower social functioning observed in BC survivors than that observed in KC survivors. Although the three groups of UC survivors showed essentially similar functioning sub-scales and symptoms when compared to the general population, PC and BC survivors showed significantly lower social functioning and a lower appetite than that observed in controls. KC survivors showed lower physical functioning, as well as higher pain and dyspnea. Although all three groups of UC survivors reported higher financial difficulties, they also reported higher perceived social support than that reported by the non-cancer control group. No statistically significant difference was observed in terms of depressive symptoms between each group of UC survivors and the general population.
Conclusion
Disease-free survivors of the three major types of UCs showed generally similar HRQoL compared to the general population, as well as compared to each other.

Citations

Citations to this article as recorded by  
  • Role performance and factors affecting quality of life in bladder cancer survivors with ileal orthotopic neobladder
    So Hee Kim, Eunjung Ryu, Byong Chang Jeong
    Asia-Pacific Journal of Oncology Nursing.2024; 11(6): 100490.     CrossRef
  • The mental and emotional status after radical cystectomy and different urinary diversion orthotopic bladder substitution versus external urinary diversion after radical cystectomy: A propensity score‐matched study
    Giuseppe Palermo, Francesco Pio Bizzarri, Eros Scarciglia, Emilio Sacco, Koosha Moosavi Seyed, Pierluigi Russo, Filippo Gavi, Battista Filomena Giovanni, Francesco Rossi, Marco Campetella, Angelo Totaro, Nazario Foschi, Marco Racioppi
    International Journal of Urology.2024; 31(12): 1423.     CrossRef
  • Factors Affecting the Health-Related Quality of Life of Patients with Bladder Cancer
    Haetsal Kwon, Hyojung Park
    Journal of Korean Public Health Nursing.2024; 38(3): 358.     CrossRef
  • Properties of the Shift and Persist Questionnaire in adolescent and young adult cancer patients and survivors: Validity, consistency, and interpretability
    Karly M. Murphy, Edith Chen, Edward H. Ip, Abby R. Rosenberg, Mallory A. Snyder, John M. Salsman
    Quality of Life Research.2023; 32(1): 273.     CrossRef
  • Adoption of patient communication rules in clinical practice and the role of faith-based communities in shaping them: the palliative aspect of spiritual support
    Konstantin Sokolovskiy, Olga Pashanova, Vladimir Beketov, Andrey Aleshkin
    Mental Health, Religion & Culture.2023; 26(1): 16.     CrossRef
  • Identifying the unmet supportive care needs of people affected by kidney cancer: a systematic review
    Amy O’Dea, Craig Gedye, Belinda Jago, Catherine Paterson
    Journal of Cancer Survivorship.2022; 16(6): 1279.     CrossRef
  • Mental Health in Urologic Oncology
    Danyon Anderson, Abrahim N. Razzak, Matthew McDonald, David Cao, Jamal Hasoon, Omar Viswanath, Alan D. Kaye, Ivan Urits
    Health Psychology Research.2022;[Epub]     CrossRef
  • Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review
    Liliana Vartolomei, Manuela Schmidinger, Mihai Vartolomei, Shahrokh Shariat
    Journal of Clinical Medicine.2022; 11(21): 6383.     CrossRef
  • Health-Related Quality of Life among Cancer Survivors Depending on the Occupational Status
    Kisook Kim, Hyohyeon Yoon
    International Journal of Environmental Research and Public Health.2021; 18(7): 3803.     CrossRef
  • Feasibility of a socio-spiritual intervention to improve quality of life of adult Nigerians with cancer and their family caregivers: Protocol for a randomised controlled trial
    Israel Gabriel, Debra Creedy, Elisabeth Coyne
    Contemporary Clinical Trials Communications.2021; 22: 100802.     CrossRef
  • Age-specific health-related quality of life in disease-free long-term prostate cancer survivors versus male population controls—results from a population-based study
    Salome Adam, Daniela Doege, Lena Koch-Gallenkamp, Melissa S. Y. Thong, Heike Bertram, Andrea Eberle, Bernd Holleczek, Ron Pritzkuleit, Mechthild Waldeyer-Sauerland, Annika Waldmann, Sylke Ruth Zeissig, Lina Jansen, Sabine Rohrmann, Hermann Brenner, Volker
    Supportive Care in Cancer.2020; 28(6): 2875.     CrossRef
  • Comorbid depression in medical diseases
    Stefan M. Gold, Ole Köhler-Forsberg, Rona Moss-Morris, Anja Mehnert, J. Jaime Miranda, Monika Bullinger, Andrew Steptoe, Mary A. Whooley, Christian Otte
    Nature Reviews Disease Primers.2020;[Epub]     CrossRef
  • Health-related Quality of Life and Its Related Factors among Cancer Survivors and General Adults: Focusing on Lifestyle Behaviors and Mental Health
    Eun A Song, Youngran Kweon, Yoon Young Hwang, Minjeong An
    Korean Journal of Adult Nursing.2020; 32(4): 385.     CrossRef
  • Age and gender differences in anxiety and depression in cancer patients compared with the general population
    Andreas Hinz, Philipp Yorck Herzberg, Florian Lordick, Joachim Weis, Hermann Faller, Elmar Brähler, Martin Härter, Karl Wegscheider, Kristina Geue, Anja Mehnert
    European Journal of Cancer Care.2019;[Epub]     CrossRef
  • 12,213 View
  • 217 Download
  • 12 Web of Science
  • 14 Crossref
Close layer
The Comparison of Oncologic Outcomes between Open and Laparoscopic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Korean Multicenter Collaborative Study
Tae Heon Kim, Bumsik Hong, Ho Kyung Seo, Seok Ho Kang, Ja Hyeon Ku, Byong Chang Jeong, on behalf of Urothelial Cancer-Advanced Research and Treatment (UCART) Study Group
Cancer Res Treat. 2019;51(1):240-251.   Published online April 24, 2018
DOI: https://doi.org/10.4143/crt.2017.417
AbstractAbstract PDFPubReaderePub
Purpose
We compared oncologic outcomes of patients with upper tract urothelial carcinoma (UTUC) who underwent open nephroureterectomy (ONU) or laparoscopic nephroureterectomy (LNU).
Materials and Methods
Consecutive cases of ONU and LNU between 2000 and 2012 at five participating institutions were included in this retrospective analysis. Clinical characteristics and pathologic outcomes were compared between the two surgical approaches. The influence of the type of surgical approach on intravesical recurrence-free survival (IVRFS), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) was analyzed using the Kaplan-Meier method and differences were assessed with the log-rank test. Predictors of IVRFS, PFS, CSS, and OS were also analyzed with a multivariable Cox regression model.
Results
A total of 1,521 patients with UTUC were eligible for the present study (ONU, 906; LNU, 615). The estimated 5-year IVRFS (57.8 vs. 51.0%, p=0.010), CSS (80.4 vs. 76.4%, p=0.032), and OS (75.8 vs. 71.4%, p=0.026) rates were significantly different between the two groups in favor of LNU. Moreover, in patients with locally advanced disease (pT3/pT4), the LNU group showed better 5-year IVRFS (62.9 vs. 54.1%, p=0.038), CSS (64.3 vs. 56.9%, p=0.022), and OS (60.4 vs. 53.1%, p=0.018) rates than the ONU group. Multivariable Cox regression analyses showed that type of surgical approach was independently associated with IVRFS, but was not related to PFS, CSS, and OS.
Conclusion
Our findings indicate that LNU provided better oncologic control of IVRFS, CSS, and OS compared with ONU for the management of patients with UTUC.

Citations

Citations to this article as recorded by  
  • Impact of lymphovascular invasion on survival in surgically treated upper tract urothelial carcinoma: a nationwide analysis
    Giuseppe Ottone Cirulli, Nicholas Corsi, Ivan Rakic, Alex Stephens, Giuseppe Chiarelli, Marco Finati, Matthew Davis, Shane Tinsley, Akshay Sood, Nicolò Buffi, Giovanni Lughezzani, Giuseppe Carrieri, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Cr
    BJU International.2024; 133(5): 555.     CrossRef
  • Robotic Radical Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma: A Trend Analysis of Utilization and a Comparative Study
    Hoyoung Bae, Jae Hoon Chung, Wan Song, Minyong Kang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Hyun Hwan Sung
    Cancers.2022; 14(10): 2497.     CrossRef
  • Impact of pathological factors on survival in patients with upper tract urothelial carcinoma: a systematic review and meta-analysis
    Gopal Sharma, Anuj Kumar Yadav, Tarun Pareek, Pawan Kaundal, Shantanu Tyagi, Sudheer Kumar Devana, Shrawan Kumar Singh
    International braz j urol.2022; 48(3): 406.     CrossRef
  • Laparoscopic compared with open nephroureterectomy in upper urinary tract urothelial carcinoma: A systemic review and a meta‐analysis
    Guihong Liu, Zeqin Yao, Guoqiang Chen, Yalang Li, Bing Liang
    International Journal of Clinical Practice.2021;[Epub]     CrossRef
  • RETRACTED: Open Nephroureterectomy Compared to Laparoscopic in Upper Urinary Tract Urothelial Carcinoma: A Meta-Analysis
    Guihong Liu, Zeqin Yao, Guoqiang Chen, Yalang Li, Bing Liang
    Frontiers in Surgery.2021;[Epub]     CrossRef
  • A retrospective multicenter comparison of conditional cancer-specific survival between laparoscopic and open radical nephroureterectomy in locally advanced upper tract urothelial carcinoma
    Sung Han Kim, Mi Kyung Song, Ja Hyeon Ku, Seok Ho Kang, Byong Chang Jeong, Bumsik Hong, Ho Kyung Seo, Isaac Yi Kim
    PLOS ONE.2021; 16(10): e0255965.     CrossRef
  • Unusual presentation of upper urinary tract urothelial carcinoma in Taiwan: Direct comparison from Taiwan‐Japan UTUC Collaboration Cohort
    Hao Lun Luo, Chikara Ohyama, Shingo Hatakeyama, Hung Jen Wang, Tohru Yoneyama, Wen Chou Yang, Yao Chi Chuang, Yen Ta Chen, Wei Chin Lee, Yuan Tso Cheng, Chih Hsiung Kang, Po Hui Chiang
    International Journal of Urology.2020; 27(4): 327.     CrossRef
  • Concomitant carcinoma in situ as a prognostic factor in the upper tract urothelial carcinoma after radical nephroureterectomy: A systematic review and meta-analysis
    Xiaoshuai Gao, Yucheng Ma, Guo Chen, Jixiang Chen, Hao Li, Hong Li, Xin Wei, Kunjie Wang
    Urologic Oncology: Seminars and Original Investigations.2020; 38(6): 574.     CrossRef
  • Transperitoneal radical nephroureterectomy is associated with worse disease progression than retroperitoneal radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma
    Tae Heon Kim, Yoon Seok Suh, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Hyun Hwan Sung
    Scientific Reports.2019;[Epub]     CrossRef
  • Diagnosis, management, and follow-up of upper tract urothelial carcinoma: an interdisciplinary collaboration between urology and radiology
    Jacob L. Roberts, Fady Ghali, Lejla Aganovic, Seth Bechis, Kelly Healy, Gerant Rivera-Sanfeliz, Riccardo Autorino, Ithaar Derweesh
    Abdominal Radiology.2019; 44(12): 3893.     CrossRef
  • Prognostic Value of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
    Wen Liu, Lijiang Sun, Fengju Guan, Fangming Wang, Guiming Zhang
    Disease Markers.2019; 2019: 1.     CrossRef
  • 8,563 View
  • 212 Download
  • 13 Web of Science
  • 11 Crossref
Close layer
Poor Preoperative Glycemic Control Is Associated with Dismal Prognosis after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Korean Multicenter Study
Sung Gu Kang, Eu Chang Hwang, Seung Il Jung, Ho Song Yu, Ho Seok Chung, Taek Won Kang, Dong Deuk Kwon, Jun Eul Hwang, Jun Seok Kim, Joon Hwa Noh, Jae Hyung You, Myung Ki Kim, Tae Hoon Oh, Ill Young Seo, Seung Baik, Chul-Sung Kim, Seok Ho Kang, Jun Cheon
Cancer Res Treat. 2016;48(4):1293-1301.   Published online March 23, 2016
DOI: https://doi.org/10.4143/crt.2016.021
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to evaluate the effect of diabetes mellitus (DM) and preoperative glycemic control on prognosis in Korean patients with upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy (RNU). Materials and Methods A total of 566 patients who underwent RNU at six institutions between 2004 and 2014 were reviewed retrospectively. Kaplan-Meier and Cox regression analyses were performed to assess the association between DM, preoperative glycemic control, and recurrence-free, cancer-specific, and overall survival.
Results
The median follow-up period was 33.8 months (interquartile range, 41.4 months). A total of 135 patients (23.8%) had DM and 67 patients (11.8%) had poor preoperative glycemic control. Patients with poor preoperative glycemic control had significantly shorter median recurrence-free, cancer-specific, and overall survival than patients with good preoperative glycemic control and non-diabetics (all, p=0.001). In multivariable Cox regression analysis, DM with poor preoperative glycemic control showed association with worse recurrence-free survival (hazard ratio [HR], 2.26; 95% confidence interval [CI], 1.31 to 3.90; p=0.003), cancer-specific survival (HR, 2.96; 95% CI, 1.80 to 4.87; p=0.001), and overall survival (HR, 2.13; 95% CI, 1.40 to 3.22; p=0.001). Conclusion Diabetic UTUC patients with poor preoperative glycemic control had significantly worse oncologic outcomes than diabetic UTUC patients with good preoperative glycemic control and non-diabetics. Further investigation is needed to elucidate the exact mechanism underlying the impact of glycemic control on UTUC treatment outcome.

Citations

Citations to this article as recorded by  
  • Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians
    Laura Ashley, Saifuddin Kassim, Ian Kellar, Lisa Kidd, Frances Mair, Mike Matthews, Mollie Price, Daniel Swinson, Johanna Taylor, Galina Velikova, Jonathan Wadsley
    BMJ Open.2022; 12(2): e060402.     CrossRef
  • Annular-shaped stenosis in the ureter: Caution should be taken
    Jie Ming, Yue Wang, Ziliang Su, Chunyang Wang
    Urologic Oncology: Seminars and Original Investigations.2022; 40(6): 274.e7.     CrossRef
  • Glycosylated haemoglobin and prognosis in 10,536 people with cancer and pre-existing diabetes: a meta-analysis with dose-response analysis
    Suping Ling, Michael Sweeting, Francesco Zaccardi, David Adlam, Umesh T. Kadam
    BMC Cancer.2022;[Epub]     CrossRef
  • Malnutrition management of hospitalized patients with diabetes/hyperglycemia and cancer cachexia
    Rosa Burgos Peláez, José Pablo Suárez Llanos, Jose Manuel García Almeida, Pilar Matía Martín, Samara Palma Milla, Alejandro Sanz Paris, Ana Zugasti Murillo, Ana Artero-Fullana, Alfonso Calañas Continente, M.ª Jesús Chinchetru, Katherine García Malpartida,
    Nutrición Hospitalaria.2022;[Epub]     CrossRef
  • The Impact of Diabetes on the Prognosis of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
    Xiaoshuai Gao, Liang Zhou, Jianzhong Ai, Wei Wang, Xingpeng Di, Liao Peng, Banghua Liao, Xi Jin, Hong Li, Kunjie Wang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • The Prognostic Value of Lymphovascular Invasion in Patients With Upper Tract Urinary Carcinoma After Surgery: An Updated Systematic Review and Meta-Analysis
    Lijin Zhang, Bin Wu, Zhenlei Zha, Hu Zhao, Jun Yuan, Yejun Feng
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • The impact of preoperative glycated hemoglobin levels on outcomes in oral squamous cell carcinoma
    Ze Yun Tay, Huang‐Kai Kao, Kuang‐Hsu Lien, Shao‐Yu Hung, Yenlin Huang, Ngan‐Ming Tsang, Kai‐Ping Chang
    Oral Diseases.2020; 26(7): 1449.     CrossRef
  • 10,826 View
  • 120 Download
  • 8 Web of Science
  • 7 Crossref
Close layer
Oncologic and Functional Outcomes after Partial Nephrectomy Versus Radical Nephrectomy in T1b Renal Cell Carcinoma: A Multicenter, Matched Case-Control Study in Korean Patients
Hoon Ah Jang, Jin Wook Kim, Seok Soo Byun, Sung Hoo Hong, Young Jun Kim, Young Hyun Park, Kyung Suk Yang, Seok Cho, Jun Cheon, Seok Ho Kang
Cancer Res Treat. 2016;48(2):612-620.   Published online June 5, 2015
DOI: https://doi.org/10.4143/crt.2014.122
AbstractAbstract PDFPubReaderePub
Purpose
The study was to compare the oncologic and functional outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) for pathologically proven T1b renal cell carcinoma using pair-matched groups.
Materials and Methods
We reviewed our prospectively maintained database for RN and PN in T1b renal tumors surgically treated between 1999 and 2011 at five institutions in Korea. Of 611 patients treated with PN or RN for a solitary and NX/N0 M0 renal mass (4-7 cm), 577 (PN, 100; RN, 477) patients with pathologically confirmed pT1b remained for analysis. Study subjects were grouped by PN or RN, then matched by age, sex, comorbidities, body mass index, tumor size and depth, histologic type, and preoperative estimated glomerular filtration rate (eGFR) using propensities score. To evaluate oncologic outcomes, overall survival (OS), cancer- specific survival (CSS), and progression-free survival (PFS) rates were analyzed. The functional outcomes were evaluated by postoperative eGFR.
Results
The median follow-up in the RN group was 48.1 and 42.6 months in the PN group. The estimated 10-year CSS rate (PN 85.7% vs. RN 84.4%, p=0.52) and 5- and estimated 10-year PFS rates (PN: 86.4% and 79.2% vs. RN: 86.0% and 66.1%, p=0.66) did not differ significantly between groups. The estimated 10-year OS rate was significantly higher in the PN group (85.7%) compared to the RN group (73.3%) (p=0.003). PN was less likely to induce new-onset chronic kidney disease (CKD) and end-stage CKD compared with RN.
Conclusion
Our study suggests that patients treated with PN demonstrate a superior OS rate and postoperative renal function with analogous CSS and PFS rates compared with pair-matched patients treated with RN.

Citations

Citations to this article as recorded by  
  • Prediction of clinically significant recurrence after partial nephrectomy. Data from the Cancer Registry of Norway with more than five years of follow-up
    Ovidiu S. Barnoiu, Tom B. Johannesen, Lien M. Diep, Eskil S. Pedersen, Karin M. Hjelle, Christian Beisland
    Scandinavian Journal of Urology.2024; 59: 1.     CrossRef
  • Comparison of Oncological and Functional Outcomes of Radical Versus Partial Nephrectomy for cT1b Renal Cell Carcinoma: A Two-Centre, Matched Analysis
    Luna van den Brink, Daniel L. van den Kroonenberg, Niels M. Graafland, Axel Bex, Harrie P. Beerlage, Jeroen R.A. van Moorselaar, Patricia J. Zondervan
    Kidney Cancer.2024; 8(1): 51.     CrossRef
  • Differences in the treatment patterns of small renal masses: A disaggregated analyses by race/ethnicity
    Samuel Carbunaru, Jordan M. Rich, Yassamin Neshatvar, Katie Murray, Madhur Nayan
    Urologic Oncology: Seminars and Original Investigations.2024; 42(12): 453.e1.     CrossRef
  • Three-dimensional visualization techniques improve surgical Decision Making of robotic-assisted partial nephrectomy
    Yuchao Wang, Qiliang Teng, Zhihong Dai, Chunyu Chen, Liren Zhang, Jiaxin Xie, Hao Wang, Zihan Xin, Sishan Chen, Yu Tai, Liang Wang, Bo Fan, Zhiyu Liu
    Heliyon.2024; 10(21): e38806.     CrossRef
  • Renal functional and cardiovascular outcomes of partial nephrectomy versus radical nephrectomy for renal tumors: a systematic review and meta-analysis
    Mario Ochoa-Arvizo, Mariano García-Campa, Karla M. Santos-Santillana, Tobias Klatte, Luis R. García-Chairez, Alejandro D. González-Colmenero, Rigoberto Pallares-Méndez, Daniel E. Cervantes-Miranda, Hiram H. Plata-Huerta, Rene- Rodriguez-Gutierrez, Adrián
    Urologic Oncology: Seminars and Original Investigations.2023; 41(3): 113.     CrossRef
  • Frequency of Benign Lesions in Radiologically Presumed Renal Cell Carcinoma Taking Histopathology as Gold Standard
    Ayesha Khan, Asad Shahzad Hassan, Naseem Akhtar, Rashid Ali, Rehan Mohsin, Altaf Hashmi, Nazish Mughal
    Pakistan Journal of Health Sciences.2023; : 51.     CrossRef
  • Laparoscopic partial versus radical nephrectomy for localized renal cell carcinoma over 4 cm
    Zi-Jun Sun, Feng Liu, Hai-Bin Wei, Da-Hong Zhang
    Journal of Cancer Research and Clinical Oncology.2023; 149(20): 17837.     CrossRef
  • Long-term oncological results of surgical treatment of localized renal tumors
    S. A. Rakul, K. V. Pozdnyakov, R. A. Eloev
    Cancer Urology.2022; 17(4): 27.     CrossRef
  • Near-Infrared Fluorescence Imaging of Renal Cell Carcinoma with ASP5354 in a Mouse Model for Intraoperative Guidance
    Katsunori Teranishi
    International Journal of Molecular Sciences.2022; 23(13): 7228.     CrossRef
  • Comparison of oncologic outcomes between elective partial and radical nephrectomy in patients with renal cell carcinoma in CT1B stadium
    Predrag Maric, Predrag Aleksic, Branko Kosevic, Mirko Jovanovic, Vladimir Bancevic, Dejan Simic, Nemanja Rancic
    Vojnosanitetski pregled.2022; 79(6): 591.     CrossRef
  • Machine learning-based prediction model for late recurrence after surgery in patients with renal cell carcinoma
    Hyung Min Kim, Seok-Soo Byun, Jung Kwon Kim, Chang Wook Jeong, Cheol Kwak, Eu Chang Hwang, Seok Ho Kang, Jinsoo Chung, Yong-June Kim, Yun-Sok Ha, Sung-Hoo Hong
    BMC Medical Informatics and Decision Making.2022;[Epub]     CrossRef
  • Comparison of the oncological, perioperative and functional outcomes of partial nephrectomy versus radical nephrectomy for clinical T1b renal cell carcinoma: A systematic review and meta-analysis of retrospective studies
    Yucong Zhang, Gongwei Long, Haojie Shang, Beichen Ding, Guoliang Sun, Wei Ouyang, Man Liu, Yuan Chen, Heng Li, Hua Xu, Zhangqun Ye
    Asian Journal of Urology.2021; 8(1): 117.     CrossRef
  • Machine Learning Approach to Predict the Probability of Recurrence of Renal Cell Carcinoma After Surgery: Prediction Model Development Study
    HyungMin Kim, Sun Jung Lee, So Jin Park, In Young Choi, Sung-Hoo Hong
    JMIR Medical Informatics.2021; 9(3): e25635.     CrossRef
  • Long-term results of surgical treatment for stage cT1 kidney cancer
    Sergey A. Rakul, Pavel N. Romashchenko, Kirill V. Pozdnyakov, Nikolay A. Maistrenko
    Bulletin of the Russian Military Medical Academy.2021; 23(3): 133.     CrossRef
  • Retroperitoneal laparoscopic partial versus radical nephrectomy for large (≥ 4 cm) and anatomically complex renal tumors: A propensity score matching study
    Wen Deng, Zhengtao Zhou, Jian Zhong, Junhua Li, Xiaoqiang Liu, Luyao Chen, Jingyu Zhu, Bin Fu, Gongxian Wang
    European Journal of Surgical Oncology.2020; 46(7): 1360.     CrossRef
  • Synchronous sporadic bilateral multiple chromophobe renal cell carcinoma accompanied by a clear cell carcinoma and a cyst: A case report
    Fan Yang, Zi-Chen Zhao, A-Jin Hu, Peng-Fei Sun, Bin Zhang, Ming-Chuan Yu, Juan Wang
    World Journal of Clinical Cases.2020; 8(14): 3064.     CrossRef
  • Peri‐operative and local control outcomes of robot‐assisted partial nephrectomy vs percutaneous cryoablation for renal masses: comparison after matching on radiological stage and renal score
    Guillaume Fraisse, Loïc Colleter, Benoit Peyronnet, Zine‐Eddine Khene, Qusay Mandoorah, Yanish Soorojebally, Ali Bourgi, Alexandre De La Taille, Morgan Roupret, Eric De Kerviler, François Desgrandchamps, Karim Bensalah, Alexandra Masson‐Lecomte
    BJU International.2019; 123(4): 632.     CrossRef
  • Organ-sparing procedures in GU cancer: part 1—organ-sparing procedures in renal and adrenal tumors: a systematic review
    Raouf Seyam, Mahmoud I. Khalil, Mohamed H. Kamel, Waleed M. Altaweel, Rodney Davis, Nabil K. Bissada
    International Urology and Nephrology.2019; 51(3): 377.     CrossRef
  • Comparison of the long-term follow-up and perioperative outcomes of partial nephrectomy and radical nephrectomy for 4 cm to 7 cm renal cell carcinoma: a systematic review and meta-analysis
    Yu-Li Jiang, Cheng-Xia Peng, Heng-Zi Wang, Lu-Jie Qian
    BMC Urology.2019;[Epub]     CrossRef
  • Partial nephrectomy versus radical nephrectomy for cT2 or greater renal tumors: a systematic review and meta-analysis
    Jingdong Li, Yanping Zhang, Zhihai Teng, Zhenwei Han
    Minerva Urologica e Nefrologica.2019;[Epub]     CrossRef
  • Analysis of survival for patients with chronic kidney disease primarily related to renal cancer surgery
    Jitao Wu, Chalairat Suk‐Ouichai, Wen Dong, Elvis Caraballo Antonio, Ithaar H. Derweesh, Brian R. Lane, Sevag Demirjian, Jianbo Li, Steven C. Campbell
    BJU International.2018; 121(1): 93.     CrossRef
  • Oncologic Outcomes of Partial Nephrectomy for Stage T3a Renal Cell Cancer
    Asaf Shvero, Ofer Nativ, Yasmin Abu-Ghanem, Dorit Zilberman, Bahouth Zaher, Max Levitt, Eddie Fridman, Orith Portnoy, Jacob Ramon, Zohar A. Dotan
    Clinical Genitourinary Cancer.2018; 16(3): e613.     CrossRef
  • External Validation of Contact Surface Area as a Predictor of Postoperative Renal Function in Patients Undergoing Partial Nephrectomy
    Miki Haifler, Benjamin T. Ristau, Andrew M. Higgins, Marc C. Smaldone, Alexander Kutikov, Amnon Zisman, Robert G. Uzzo
    Journal of Urology.2018; 199(3): 649.     CrossRef
  • Survival outcomes in patients with large (≥7cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-up
    M. W. W. Janssen, J. Linxweiler, S. Terwey, S. Rugge, C.-H. Ohlmann, F. Becker, Ch. Thomas, A. Neisius, J. W. Thüroff, S. Siemer, M. Stöckle, F. C. Roos, Christian Schwentner
    PLOS ONE.2018; 13(5): e0196427.     CrossRef
  • Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study
    Takaaki Hasegawa, Takashi Yamanaka, Hideo Gobara, Masaya Miyazaki, Haruyuki Takaki, Yozo Sato, Yoshitaka Inaba, Koichiro Yamakado
    Japanese Journal of Radiology.2018; 36(9): 551.     CrossRef
  • Néphrectomie partielle pour tumeur de plus de 7 cm : morbidité, résultats oncologiques et fonctionnels (UroCCR-7 study)
    J. Rouffilange, A. Gobet, G. Capon, V. Comat, S. Lagabrielle, A. Guillaume, G. Robert, H. Bensadoun, J.-M. Ferrière, J.-C. Bernhard
    Progrès en Urologie.2018; 28(12): 588.     CrossRef
  • Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies
    Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino
    European Urology.2017; 71(4): 606.     CrossRef
  • Utilization trends and outcomes up to 3 months of open, laparoscopic, and robotic partial nephrectomy
    Jamie S. Pak, Jason J. Lee, Khawaja Bilal, Mark Finkelstein, Michael A. Palese
    Journal of Robotic Surgery.2017; 11(2): 223.     CrossRef
  • Early surgical outcomes and oncological results of robot‐assisted partial nephrectomy: a multicentre study
    Rajan Veeratterapillay, Sanjai K. Addla, Clare Jelley, John Bailie, David Rix, Steve Bromage, Neil Oakley, Robin Weston, Naeem A. Soomro
    BJU International.2017; 120(4): 550.     CrossRef
  • External validation of the Arterial Based Complexity (ABC) scoring system in renal tumors treated by minimally invasive partial nephrectomy
    Liangyou Gu, Xin Ma, Hongzhao Li, Yuanxin Yao, Yongpeng Xie, Luyao Chen, Yu Gao, Xu Zhang
    Journal of Surgical Oncology.2017; 116(4): 507.     CrossRef
  • Partial nephrectomy vs. radical nephrectomy for renal tumors: A meta-analysis of renal function and cardiovascular outcomes
    Zheng Wang, Ganggang Wang, Qinghua Xia, Zhenhua Shang, Xiao Yu, Muwen Wang, Xunbo Jin
    Urologic Oncology: Seminars and Original Investigations.2016; 34(12): 533.e11.     CrossRef
  • Novel Use of Folate-Targeted Intraoperative Fluorescence, OTL38, in Robot-Assisted Laparoscopic Partial Nephrectomy: Report of the First Three Cases
    Cheuk Fan Shum, Clinton D. Bahler, Philip S. Low, Timothy L. Ratliff, Steven V. Kheyfets, Jay P. Natarajan, George E. Sandusky, Chandru P. Sundaram
    Journal of Endourology Case Reports.2016; 2(1): 189.     CrossRef
  • Recommandations en onco-urologie 2016-2018 du CCAFU : Cancer du rein
    K. Bensalah, L. Albiges, J.-C. Bernhard, P. Bigot, T. Bodin, R. Boissier, J.-M. Corréas, P. Gimel, J.-A. Long, F.-X. Nouhaud, I. Ouzaïd, P. Paparel, N. Rioux-Leclercq, A. Méjean
    Progrès en Urologie.2016; 27: S27.     CrossRef
  • 13,659 View
  • 187 Download
  • 35 Web of Science
  • 33 Crossref
Close layer
Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?
Sang Hyub Lee, Hee Seo Son, Seok Cho, Sang Jin Kim, Dae Seon Yoo, Seok Ho Kang, Sung Yul Park, Jinsung Park, Sung-Goo Chang, Seung Hyun Jeon
Cancer Res Treat. 2015;47(3):489-494.   Published online November 17, 2014
DOI: https://doi.org/10.4143/crt.2014.013
AbstractAbstract PDFPubReaderePub
Purpose
Up to 10% of recurrences develop beyond 5 years after curative treatment of localized renal cell carcinoma (RCC). Clinicopathologic features were evaluated to determine which factors are associated with late recurrence.
Materials and Methods
A total of 753 patients were diagnosed with localized RCC from January 2000 to June 2008. We enrolled 225 patients who were treated surgically and had a minimal recurrence-free survival of 60 months. Patients who had recurrence beyond 5 years after nephrectomy were defined as the late recurrence group and the remaining patients as the recurrence-free group. Multivariate logistic regression analyses and the Cox proportional hazard model were used for determination of features associated with late recurrence.
Results
In multivariate analyses, age older than 60 (p=0.030), Fuhrman grade ≥ 3 (p=0.042), and pT stage ≥ pT2 (p=0.010) showed statistical association with late recurrence. The Cox proportional hazard model showed significant differences in recurrence-free survival when we classified the patients based on pT2 (p=0.007) and on patient age ≥ 60 years (p=0.039).
Conclusion
Patient age greater than 60 years, Fuhrman grade ≥ 3, and tumor stage ≥ pT2 are independent risk factors of recurrence more than 5 years after surgery in patients with RCC. Therefore, close lifelong follow-up is recommended for patients with these risk factors.

Citations

Citations to this article as recorded by  
  • Comparison of the Efficacy of Percutaneous Microwave Ablation Therapy versus Laparoscopic Partial Nephrectomy for Early-Stage Renal Tumors
    Osman Kula, Yeliz Ateş, Hakkı Mete Çek, Atınç Tozsin, Burak Günay, Burak Akgül, Selçuk Korkmaz, Gökhan Karataş, Serdar Solak, Fethi Emre Ustabaşıoğlu, Ersan Arda
    Diagnostics.2024; 14(14): 1574.     CrossRef
  • Machine Learning Approach to Predict the Probability of Recurrence of Renal Cell Carcinoma After Surgery: Prediction Model Development Study
    HyungMin Kim, Sun Jung Lee, So Jin Park, In Young Choi, Sung-Hoo Hong
    JMIR Medical Informatics.2021; 9(3): e25635.     CrossRef
  • Risk‐adjusted proposal for >60 months follow up after surgical treatment of organ‐confined renal cell carcinoma according to life expectancy
    Sebastian K Frees, Mohammed M Kamal, Sebastian Nestler, Patrick MF Levien, Samir Bidnur, Walburgis Brenner, Christian Thomas, Wolfgang Jaeger, Joachim W Thüroff, Frederik C Roos
    International Journal of Urology.2019; 26(3): 385.     CrossRef
  • Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis
    Johannes Uhlig, Arne Strauss, Gerta Rücker, Ali Seif Amir Hosseini, Joachim Lotz, Lutz Trojan, Hyun S. Kim, Annemarie Uhlig
    European Radiology.2019; 29(3): 1293.     CrossRef
  • 13,616 View
  • 82 Download
  • 6 Web of Science
  • 4 Crossref
Close layer
Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment
Jung Hyun Lee, Sung Gu Kang, Seung Tae Kim, Seok Ho Kang, In Keun Choi, Young Je Park, Sang Chul Oh, Deuk Jae Sung, Jae Hong Seo, Jun Cheon, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim, Kyong Hwa Park
Cancer Res Treat. 2014;46(2):172-177.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.172
AbstractAbstract PDFPubReaderePub
Purpose

There is no established standard second-line chemotherapy for patients with advanced or metastatic urothelial carcinoma (UC) who failed gemcitabine and cisplatin (GC) chemotherapy. This study was conducted in order to investigate the efficacy and toxicity of modified methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in patients with metastatic UC previously treated with GC.

Materials and Methods

We retrospectively analyzed 28 patients who received modified MVAC between November 2004 and November 2012. All patients failed prior, first-line GC chemotherapy.

Results

The median age of patients was 64.0 years (range, 33.0 to 77.0 years), and 23 (82.1%) patients had an Eastern Cooperative Oncology Group performance status of 0 or 1. The overall response rate and the disease control rate were 36.0% and 64.0%, respectively. After a median follow-up period of 38 weeks (range, 5 to 182 weeks), median progression free survival was 21.0 weeks (95% confidence interval [CI], 6.3 to 35.7 weeks) and median overall survival was 49.0 weeks (95% CI, 18.8 to 79.3 weeks). Grade 3 or 4 hematological toxicities included neutropenia (n=21, 75.0%) and anemia (n=9, 32.1%). Grade 3 or 4 non-hematological toxicities did not occur and there was no treatment-related death.

Conclusion

Modified MVAC appears to be a safe and active chemotherapy regimen in patients with stable physical status and adequate renal function after GC treatment.

Citations

Citations to this article as recorded by  
  • Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis
    Teruki Isobe, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Satoshi Nozaki, Keitaro Iida, Yusuke Noda, Nobuhiko Shimizu, Nami Tomiyama, Rika Banno, Hiroki Kubota, Shuzo Hamamoto, Ryosuke Ando, Noriyasu Kawai, Takahiro Yasui
    International Journal of Clinical Oncology.2022; 27(1): 165.     CrossRef
  • SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer
    Axel S. Merseburger, Andrea B. Apolo, Simon Chowdhury, Noah M. Hahn, Matthew D. Galsky, Matthew I. Milowsky, Daniel Petrylak, Tom Powles, David I. Quinn, Jonathan E. Rosenberg, Arlene Siefker-Radtke, Guru Sonpavde, Cora N. Sternberg
    World Journal of Urology.2019; 37(1): 95.     CrossRef
  • Efficacy of Different Second-line Therapy Regimens in Metastatic Urothelial Carcinoma
    Lukas Barwitz, Anne Berger, Stefanie Zschaebitz, Max Jenzer, Cathleen Nientiedt, Stefan Duensing, Dirk Jäger, Dogu Teber, Markus Hohenfellner, Carsten Grüllich
    The Open Urology & Nephrology Journal.2017; 10(1): 52.     CrossRef
  • Cisplatin- Versus Non–Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin
    Jennifer A. Locke, Gregory Russell Pond, Guru Sonpavde, Andrea Necchi, Patrizia Giannatempo, Ravi Kumar Paluri, Guenter Niegisch, Peter Albers, Carlo Buonerba, Giuseppe Di Lorenzo, Ulka N. Vaishampayan, Scott A. North, Neeraj Agarwal, Syed A. Hussain, Sum
    Clinical Genitourinary Cancer.2016; 14(4): 331.     CrossRef
  • Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature
    Christoph Oing, Michael Rink, Karin Oechsle, Christoph Seidel, Gunhild von Amsberg, Carsten Bokemeyer
    Journal of Urology.2016; 195(2): 254.     CrossRef
  • Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP)
    Ki Hong Kim, Sung Joon Hong, Kyung Seok Han
    BMC Cancer.2015;[Epub]     CrossRef
  • 12,531 View
  • 90 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Biopsy Related Prostate Status Does Not Affect on the Clinicopathological Outcome of Robotic Assisted Laparoscopic Radical Prostatectomy
Hoon Choi, Young Hwii Ko, Sung Gu Kang, Seok Ho Kang, Hong Seok Park, Jun Cheon, Vipul R. Patel
Cancer Res Treat. 2009;41(4):205-210.   Published online December 31, 2009
DOI: https://doi.org/10.4143/crt.2009.41.4.205
AbstractAbstract PDFPubReaderePub
Purpose

To determine whether the biopsy core number and time interval between prostate biopsy and radical prostatectomy affect the operative and oncologic outcome of robot assisted laparoscopic radical prostatectomy (RALP).

Materials and Methods

From January 2008 to April 2009, a single surgeon performed 72 RALPs after an initial learning period of 30 cases. The relationship between time from biopsy to prostatectomy and biopsy core number with operative time and estimated blood loss (EBL) were initially evaluated with a linear regression model. These patients were classified into groups according to whether the interval from biopsy to RALP was within four weeks or not, and whether there were less than or greater than 10 core specimens removed.

Results

RALP was performed in 34 patients within four weeks of biopsy, and in 38 patients more than 4 weeks after biopsy. According to the number of core specimens removed, less than 10 cores were performed in 10 patients, and more than 10 cores were performed in 62 patients. Using an interval of 4 weeks as the cutoff point, early surgery was associated with longer operating time (232.6 vs 208.8 min) and increased estimated blood loss (305.1 vs 276.9 mL). For cases with more than 10 biopsy cores, there was a slight increase in operative time (229.2 vs 210.3 min). None of these differences were statistically significant by multivariate analysis.

Conclusion

Our data suggests that there is no reason to delay RALP to more than 4 weeks after prostate biopsy. It also revealed that the number of biopsy cores (up to 14) did not influence operative outcome. Thus, RALP is a feasible procedure regardless of the biopsy related prostate state.

Citations

Citations to this article as recorded by  
  • Effect of Transperineal Versus Transrectal Prostate Biopsy on the Quality of Hydrogel Spacer Placement in Men Prior to Radiation Therapy for Prostate Cancer
    Michael E. Rezaee, Ulysses Gardner, Mark N. Alshak, Stephen C. Greco, Daniel Y. Song, Michael Goldstein, Christian P. Pavlovich
    Urology.2023; 182: 27.     CrossRef
  • Does time interval between prostate biopsy and surgery affect outcomes of radical prostatectomy? A systematic review and meta-analysis
    Jie Li, Qing Jiang, Qiubo Li, Yuanfeng Zhang, Liang Gao
    International Urology and Nephrology.2020; 52(4): 619.     CrossRef
  • Short interval of biopsy to robotic-assisted laparoscopic radical prostatectomy does not render any adverse effects on the perioperative outcomes
    Minke He, Yaohui Li, Zhuoyi Xiang, Li-an Sun, Yanjun Zhu, Xiaoyi Hu, Jianming Guo, Hang Wang
    Medicine.2018; 97(36): e11686.     CrossRef
  • A Multidimensional Analysis of Prostate Surgery Costs in the United States: Robotic-Assisted versus Retropubic Radical Prostatectomy
    Akash Bijlani, April E. Hebert, Mike Davitian, Holly May, Mark Speers, Robert Leung, Nihal E. Mohamed, Henry S. Sacks, Ashutosh Tewari
    Value in Health.2016; 19(4): 391.     CrossRef
  • Interval from Prostate Biopsy to Radical Prostatectomy Does Not Affect Immediate Operative Outcomes for Open or Minimally Invasive Approach
    Bumsoo Park, Seol Ho Choo, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi
    Journal of Korean Medical Science.2014; 29(12): 1688.     CrossRef
  • Interval from Prostate Biopsy to Robot-Assisted Laparoscopic Radical Prostatectomy (RALP): Effects on Surgical Difficulties
    In Sung Kim, Woong Na, Jung Su Nam, Jong Jin Oh, Chang Wook Jeong, Sung Kyu Hong, Seok Soo Byun, Sang Eun Lee
    Korean Journal of Urology.2011; 52(10): 664.     CrossRef
  • Prostate-Specific Antigen Density as a Powerful Predictor of Extracapsular Extension and Positive Surgical Margin in Radical Prostatectomy Patients with Prostate-Specific Antigen Levels of Less than 10 ng/ml
    Jin-Seok Chang, Hoon Choi, Young-Seop Chang, Jin-Bum Kim, Mi Mi Oh, Du Geon Moon, Jae Hyun Bae, Jun Cheon
    Korean Journal of Urology.2011; 52(12): 809.     CrossRef
  • 9,520 View
  • 51 Download
  • 7 Crossref
Close layer
A Matched-cohort Comparison of Laparoscopic Renal Cryoablation using Ultra-thin Cryoprobes with Open Partial Nephrectomy for the Treatment of Small Renal Cell Carcinoma
Young Hwii Ko, Hong Seok Park, Du Geon Moon, Jeong Gu Lee, Je Jong Kim, Duck Ki Yoon, Seok Ho Kang, Jun Cheon
Cancer Res Treat. 2008;40(4):184-189.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.184
AbstractAbstract PDFPubReaderePub
Purpose

To evaluate the feasibility and efficacy of performing laparoscopic renal cryoablation (LRC) for the treatment of RCC, as compared with open partial nephrectomy (OPN), which is the established NSS.

Materials and Methods

From April 2004, among the patients who underwent LRC with a 1.47 mm cryoprobe, we enrolled 20 patients who were pathologically confirmed as having RCC with a tumor size smaller than 4 cm. These patients were matched with a group of 20 patients, who were selected based on the pre-operative characteristics of the tumor and those of the patients, from a pre-existing database of the patients who underwent OPN during the same period.

Results

The mean age and tumor size were 56.3±11.5 years and 2.4±1.7 cm in the LRC group, and 57.6±10.9 years and 2.2±1.1 cm in the OPN group. The two groups were similar for their age, gender, BMI, ASA, the tumor characteristics and the indications for operation. While the pathologic results and the operation time showed similarity, the EBL (98±87 ml vs 351±147 ml, respectively, p=0.001), the transfusion rate (10% vs 40%, respectively, p=0.03) and the hospital stay (4.2±1.5 days vs 8.2±2.4 days, respectively, p=0.005) were significantly less in the LRC group. Major complications did not occur in the LRC group, but in the OPN group, one patient experienced urine leakage and one patient had a perirenal hematoma. During the mean follow up of 27.3±10.8 months and 28.7±14.9 months for each group, respectively, all the patients remained disease-free with no evidence of local recurrence or metastases.

Conclusions

LRC using ultra-thin cryoprobes for the treatment of small RCC showed similar effective oncologic results with the merits of minimal invasiveness, as compared with OPN, during the intermediate term follow up.

Citations

Citations to this article as recorded by  
  • Stage IA papillary and chromophobe renal cell carcinoma: effectiveness of cryoablation and partial nephrectomy
    Annemarie Uhlig, Johannes Uhlig, Brian Shuch, Hyun S. Kim
    Insights into Imaging.2024;[Epub]     CrossRef
  • Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis
    Takafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, Reza Sari Motlagh, Hadi Mostafaei, Fahad Quhal, Ekaterina Laukhtina, Pawel Rajwa, Abdulmajeed Aydh, Frederik König, Maximilian Pallauf, Benjamin Pradere, Jun Miki, Takahiro Kimura, Shin Egawa, Shahrokh
    Urologic Oncology: Seminars and Original Investigations.2022; 40(7): 315.     CrossRef
  • Partial nephrectomy vs cryoablation for T1a renal cell carcinoma: A comparison of survival benefit stratified by tumour size
    Xinyang Liao, Shi Qiu, Wanyu Wang, Xiaonan Zheng, Kun Jin, Shiyu Zhang, Yige Bao, Lu Yang, Qiang Wei
    Cancer Epidemiology.2019; 59: 221.     CrossRef
  • Partial nephrectomy versus ablative therapies for cT1a renal masses: A Systematic Review and meta-analysis
    Xu Hu, Yan-Xiang Shao, Yan Wang, Zhi-Qiang Yang, Wei-Xiao Yang, Xiang Li
    European Journal of Surgical Oncology.2019; 45(9): 1527.     CrossRef
  • Comparison among cryoablation, radiofrequency ablation, and partial nephrectomy for renal cell carcinomas sized smaller than 2 cm or sized 2–4 cm
    Shuai Yan, Wei Yang, Cheng-mei Zhu, Pei-meng Yan, Zhi-chao Wang
    Medicine.2019; 98(21): e15610.     CrossRef
  • Ablative Therapy for Small Renal Masses
    Benjamin L. Taylor, S. William Stavropoulos, Thomas J. Guzzo
    Urologic Clinics of North America.2017; 44(2): 223.     CrossRef
  • A national study of kidney graft tumor treatments: Toward ablative therapy
    Kerem Guleryuz, Arnaud Doerfler, Ricardo Codas, Grégoire Coffin, Jacques Hubert, Eric Lechevallier, Xavier Tillou, L. Badet, B. Barrou, T. Bessede, P. Blanchet, J.M. Boutin, J. Branchereau, T. Culty, V. Delaporte, F. Gaudez, M. Gigante, G. Karam, F. Klein
    Surgery.2016; 160(1): 237.     CrossRef
  • Guía de manejo del carcinoma de células renales
    William Quiroga Matamoros, Fernando Fernandez, Danilo Citarella Otero, Jaime Rangel, Andrea Estrada Guerrero, Iván Darío Patiño
    Urología Colombiana.2016; 25(2): 169.     CrossRef
  • Current Status of Cryotherapy for Prostate and Kidney Cancer
    Seok Cho, Seok Ho Kang
    Korean Journal of Urology.2014; 55(12): 780.     CrossRef
  • Retrospective Comparison of Laparoscopic Partial Nephrectomy Versus Laparoscopic Renal Cryoablation for Small (<3.5 cm) Cortical Renal Masses
    Georgios Haramis, Joseph A. Graversen, Adam C. Mues, Ruslan Korets, Juan Carlos Rosales, Zhamshid Okhunov, Ketan K. Badani, Mantu Gupta, Jaime Landman
    Journal of Laparoendoscopic & Advanced Surgical Techniques.2012; 22(2): 152.     CrossRef
  • Systematic Review of Perioperative and Quality-of-life Outcomes Following Surgical Management of Localised Renal Cancer
    Steven MacLennan, Mari Imamura, Marie C. Lapitan, Muhammad Imran Omar, Thomas B.L. Lam, Ana M. Hilvano-Cabungcal, Pam Royle, Fiona Stewart, Graeme MacLennan, Sara J. MacLennan, Philipp Dahm, Steven E. Canfield, Sam McClinton, T.R. Leyshon Griffiths, Börje
    European Urology.2012; 62(6): 1097.     CrossRef
  • Systematic Review of Oncological Outcomes Following Surgical Management of Localised Renal Cancer
    Steven MacLennan, Mari Imamura, Marie C. Lapitan, Muhammad Imran Omar, Thomas B.L. Lam, Ana M. Hilvano-Cabungcal, Pam Royle, Fiona Stewart, Graeme MacLennan, Sara J. MacLennan, Steven E. Canfield, Sam McClinton, T.R. Leyshon Griffiths, Börje Ljungberg, Ja
    European Urology.2012; 61(5): 972.     CrossRef
  • Perioperative, Oncologic, and Functional Outcomes of Laparoscopic Renal Cryoablation and Open Partial Nephrectomy: A Matched Pair Analysis
    Tobias Klatte, Julian Mauermann, Gertraud Heinz-Peer, Matthias Waldert, Peter Weibl, Hans Christoph Klingler, Mesut Remzi
    Journal of Endourology.2011; 25(6): 991.     CrossRef
  • 9,489 View
  • 81 Download
  • 13 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP